<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05030922</url>
  </required_header>
  <id_info>
    <org_study_id>20/00301</org_study_id>
    <nct_id>NCT05030922</nct_id>
  </id_info>
  <brief_title>Cardiovascular Risk Reduction-Diet in Pregnancy - Follow up 20 Years After the &quot;CARRDIP&quot;-Trial</brief_title>
  <acronym>CARRDIP20</acronym>
  <official_title>Cardiovascular Risk Reduction-Diet in Pregnancy - Follow up 20 Years After the &quot;CARRDIP&quot;-Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Per Ole Iversen, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oslo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The &quot;Cardiovascular Risk Reduction-Diet in Pregnancy&quot; (CARRDIP) - is a randomised controlled&#xD;
      trial with dietary intervention during pregnancy. The participants were enrolled in Norway 20&#xD;
      years ago and consisted of 269 pregnant, healthy mothers. The participants were randomised&#xD;
      1:1 to either intervention-diet or control. The intervention diet was build upon an&#xD;
      anti-atherogenic principle and was a so called &quot;Mediterranean diet&quot;. The participants were&#xD;
      monitored during pregnancy, and mother and child participated in a follow-up study 1 year&#xD;
      after birth. The current &quot;CARRDIP20&quot; trial is a follow-up of the same participants, both&#xD;
      mother and offspring, 20 years after the original intervention to measure and analyse the&#xD;
      cardiovascular health and compare the intervention group to the control group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular health score</measure>
    <time_frame>1 day</time_frame>
    <description>Cardiovascular risk score by use of the most appropriate available risk score algorithm available at time of analysis, at present the preferred calculator is Life's Simple 7 - The American Heart Association https://doi.org/10.1161/CIRCULATIONAHA.109.192703</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood samples - Lipid profile</measure>
    <time_frame>1 day</time_frame>
    <description>Ratio of non-HDL cholesterol to HDL cholesterol in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood samples - Lipid profile</measure>
    <time_frame>1 day</time_frame>
    <description>Lipoprotein a concentration in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometry</measure>
    <time_frame>1 day</time_frame>
    <description>Waist-to-hip ratio (WHR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body fat percentage</measure>
    <time_frame>1 day</time_frame>
    <description>Measured by bioimpedance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ultrasound examination of liver</measure>
    <time_frame>1 day</time_frame>
    <description>Ultrasound-Guided Attenuation Parameter (UGAP) of liver</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ultrasound examination of carotid artery</measure>
    <time_frame>1 day</time_frame>
    <description>Intima-media thickness in carotid artery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood samples - Glukose metabolism</measure>
    <time_frame>1 day</time_frame>
    <description>Hemoglobin A1c concentration in blood as a measure of long term blood sugar levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean arterial pressure (MAP)</measure>
    <time_frame>1 day</time_frame>
    <description>Measured by</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">538</enrollment>
  <condition>Nutrition</condition>
  <arm_group>
    <arm_group_label>Diet intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Follow up of both mother and offspring 20 years after allocation to an antiatherogenic diet during pregnancy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Follow up of both mother and offspring 20 years after allocation to control group during pregnancy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Antiatherogenic diet</intervention_name>
    <description>Participants instructed in antiatherogenic diet during pregnancy with frequent follow-ups to ensure compliance</description>
    <arm_group_label>Diet intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria from original CARRDIP-trial:&#xD;
&#xD;
          -  Non-smoking pregnant women&#xD;
&#xD;
          -  BMI 19 to 32 kg/m2 at inclusion&#xD;
&#xD;
          -  Age 21 to 38 years&#xD;
&#xD;
          -  Carrying a single foetus&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous pregnancy complications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Oslo</name>
      <address>
        <city>Oslo</city>
        <zip>0254</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <link>
    <url>https://www.med.uio.no/imb/forskning/prosjekter/hjertevennlig-kost-graviditet-langtidsoppfolging/</url>
    <description>Link to project homepage on University of Oslo domain (norwegian)</description>
  </link>
  <reference>
    <citation>Khoury J, Haugen G, Tonstad S, Frøslie KF, Henriksen T. Effect of a cholesterol-lowering diet during pregnancy on maternal and fetal Doppler velocimetry: the CARRDIP study. Am J Obstet Gynecol. 2007 Jun;196(6):549.e1-7.</citation>
    <PMID>17547890</PMID>
  </reference>
  <reference>
    <citation>Khoury J, Henriksen T, Christophersen B, Tonstad S. Effect of a cholesterol-lowering diet on maternal, cord, and neonatal lipids, and pregnancy outcome: a randomized clinical trial. Am J Obstet Gynecol. 2005 Oct;193(4):1292-301.</citation>
    <PMID>16202717</PMID>
  </reference>
  <reference>
    <citation>Khoury J, Henriksen T, Seljeflot I, Mørkrid L, Frøslie KF, Tonstad S. Effects of an antiatherogenic diet during pregnancy on markers of maternal and fetal endothelial activation and inflammation: the CARRDIP study. BJOG. 2007 Mar;114(3):279-88.</citation>
    <PMID>17217362</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 20, 2021</study_first_submitted>
  <study_first_submitted_qc>August 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Oslo</investigator_affiliation>
    <investigator_full_name>Per Ole Iversen, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no current plan to share individual patient data due to limitations in ethical approval and data protection considerations of the project.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

